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Mono- and Di-Fucosylated Glycans of the Parasitic Worm
S. mansoni are Recognized Differently by the Innate Immune
Receptor DC-SIGN
Apoorva D. Srivastava+,[a] Luca Unione+,[a] Margreet A. Wolfert,[a, b] Pablo Valverde,[c]
Ana Ard#,[c] Jesffls Jim8nez-Barbero,[c, d, e] and Geert-Jan Boons*[a, b, f]
Abstract: The parasitic worm, Schistosoma mansoni, express-
es unusual fucosylated glycans in a stage-dependent
manner that can be recognized by the human innate
immune receptor DC-SIGN, thereby shaping host immune
responses. We have developed a synthetic approach for
mono- and bis-fucosylated LacdiNAc (LDN-F and LDN-DF, re-
spectively), which are epitopes expressed on glycolipids and
glycoproteins of S. mansoni. It is based on the use of mono-
saccharide building blocks having carefully selected amino-
protecting groups, facilitating high yielding and stereoselec-
tive glycosylations. The molecular interaction between the
synthetic glycans and DC-SIGN was studied by NMR and mo-
lecular modeling, which demonstrated that the a1,3-fuco-
side of LDN-F can coordinate with the Ca2 +-ion of the can-
onical binding site of DC-SIGN allowing for additional inter-
actions with the underlying LDN backbone. The 1,2-fucoside
of LDN-DF can be complexed in a similar manner, however,
in this binding mode GlcNAc and GalNAc of the LDN back-
bone are placed away from the protein surface resulting in a
substantially lower binding affinity. Glycan microarray bind-
ing studies showed that the avidity and selectivity of bind-
ing is greatly enhanced when the glycans are presented
multivalently, and in this format Lex and LDN-F gave strong
responsiveness, whereas no binding was detected for LDN-
DF. The data indicates that S. mansoni has developed a strat-
egy to avoid detection by DC-SIGN in a stage-dependent
manner by the addition of a fucoside to a number of its li-
gands.
Introduction
Schistosomes are parasitic helminths that infect over 250 mil-
lion people worldwide and are responsible for 280 000 deaths
annually.[1] They can manipulate the host’s immune system to
establish chronic infections. Although the molecular basis of
these immune-modulatory mechanisms remains poorly under-
stood, it has been established that glycans of schistosomes
can induce specific innate immune responses in the infected
host, which in turn affects adaptive immunity. This occurs
through an interplay between Toll like receptors (TLRs) and C-
Type lectin receptors (CLRs) of dendritic cells (DCs) thereby
tuning immune responses toward an immune activation or tol-
erant state.[2] Schistosomes can biosynthesize a vast array of
glycoconjugates, many of which are expressed at specific
stages of their complex life cycle. The glycoproteins and glyco-
lipids of schistosomes lack sialic acid and contain a variety of
terminal glycan epitopes, including fucosylated antigens such
[a] A. D. Srivastava,+ Dr. L. Unione,+ Dr. M. A. Wolfert, Prof. Dr. G.-J. Boons
Department of Chemical Biology and Drug Discovery
Utrecht Institute for Pharmaceutical Sciences
Bijvoet Center for Biomolecular Research
Utrecht University
Universiteitsweg 99, 3584 CG Utrecht (Netherlands)
E-mail : g.j.p.h.boons@uu.nl
[b] Dr. M. A. Wolfert, Prof. Dr. G.-J. Boons
Complex Carbohydrate Research Center, University of Georgia
315 Riverbend Road, Athens, GA 30602 (USA)
[c] Dr. P. Valverde, Dr. A. Ard#, Prof. Dr. J. Jim8nez-Barbero
Molecular Recognition and Host-Pathogen Interactions
CIC bioGUNE
Bizkaia Technology Park, Building 800, 48162 Derio, Bizkaia (Spain)
[d] Prof. Dr. J. Jim8nez-Barbero
Basque Foundation for Science, Ikerbasque
48013 Bilbao, Bizkaia (Spain)
[e] Prof. Dr. J. Jim8nez-Barbero
Department of Organic Chemistry II, UPV/EHU
University of the Basque Country
48940 Leioa, Bizkaia (Spain)
[f] Prof. Dr. G.-J. Boons
Department of Chemistry, University of Georgia
Athens, GA 30602 (USA)
[+] These authors contributed equally to this work.
Supporting information and the ORCID identification number(s) for the au-
thor(s) of this article can be found under :
https ://doi.org/10.1002/chem.202002619.
T 2020 The Authors. Chemistry - A European Journal published by Wiley-
VCH GmbH. This is an open access article under the terms of Creative Com-
mons Attribution NonCommercial License, which permits use, distribution
and reproduction in any medium, provided the original work is properly
cited and is not used for commercial purposes.
Part of a Special Issue celebrating the 1000th Issue of Chemistry—A Euro-
pean Journal.




as, Lewisx (Lex), pseudo-Lewisy (pseudo_Ley), GalNAcb1,4-
(Fuca1,3)GlcNAc (LDN-F), Fuca1,3GalNAcb1,4(Fuca1,3)GlcNAc
(F-LDN-F), GalNAcb1,4(Fuca1,2Fuca1,3)GlcNAc (LDN-DF) and
Fuca1,2Fuca1,3GalNAcb1,4(Fuca1,2Fuca1,3)GlcNAc (DF-LDN-
DF) (Table 1).[3] These glycan motifs are rarely found in mam-
malian glycoconjugates but are typical signatures of schisto-
somes.[4]
Dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-
SIGN), which is a C-type lectin expressed by immature dendrit-
ic cells, has been implicated in schistosomiasis.[5] DC-SIGN can
recognize fucosylated glycan moieties presented by S. manso-
ni, such as Lex,[3b, 6] LDN-F,[3a, 5a] and pseudo_Ley.[7] Further fuco-
sylation of these motifs to give LDN-DF or DF-LDN-DF appears
to abolish detection by DC-SIGN.[3a]
The carbohydrate binding site of DC-SIGN is composed of a
wide solvent exposed surface flanked by a flexible loop, con-
ferring broad glycan binding selectivity.[8] As a matter of fact,
in addition to fucosylated glycans, high-mannose structures
can also be recognized by DC-SIGN. Most structural studies
dealing with DC-SIGN-glycan binding have focused on high
mannose-containing oligosaccharides.[9] Conversely, a structural
understanding of binding of fucosyl containing glycans derived
from S. mansoni is limited to Lex.[6b] A structural model, based
on docking, indicates that the binding of pseudo_Ley occurs
through rearrangement of the protein to accommodate the
additional fucoside at galactoside, and supports substantial
plasticity of DC-SIGN.[7] Thus, it is surprising that bis-fucosylat-
ed glycans such as LDN-DF are not recognized by DC-SIGN
calling for further studies.
Here, we report the first chemical synthesis of LDN-DF and
LDN-F by a convergent block synthetic approach. The com-
pounds were obtained in ample quantities making it possible
to examine their molecular interactions with DC-SIGN using
STD-NMR, chemical shift perturbation, trNOESY and molecular
modeling studies. It was found that DC-SIGN can interact with
the terminal fucoside of LDN-DF, however, no further interac-
tions are possible with the underlying glycan resulting in a low
affinity binding. On the other hand, the binding of LDN-F leads
to interactions of the fucoside, the GalNAc moiety and the
acetyl group of GlcNAc of the underlying LDN motif, leading
to a substantial higher affinity. The binding of DC-SIGN with
LDN-DF, LDN-F, Lex and Lex-Lex and SLex-Lex was also examined
in a glycan microarray format, which showed strong respon-
siveness of Lex and LDN-F but no binding to LDN-DF was ob-
served, indicating that through multivalent interactions avidity
and selectivity of binding is substantially enhanced. The data
indicates that S. mansoni has developed a strategy to avoid de-
tection by DC-SIGN by the addition of a fucoside to its ligands.
Results and Discussion
Chemical synthesis
The preparation of Schistosoma-derived glycans has received
relatively little attention,[10] and the chemical synthesis of LDN-
DF has not been reported. The latter compound represents a
challenging synthetic target because it requires careful selec-
tion of amino protecting groups to construct an LDN deriva-
tive that can be glycosylated with a fucosyl donor having a
temporary protecting group at C-2 to allow installation of the
subsequent 1,2-linked fucoside. The amino protecting groups
need to be selected in such a way that they promote the intro-
duction of b-glycosides, but do not sterically block the intro-
duction of the 1,3-fucoside. Furthermore, the target com-
pounds need to be modified by an aminopentyl linker, which
is required for glycan microarray printing.
We have found that the monosaccharide building blocks 1–
4 are appropriate for the assembly of aminopentyl modified
LDN-F (12) and LDN-DF (20) (Scheme 1). In this respect, the
NHTroc protecting group of 1 assures that a b-glycoside is
formed when glycosylated with acceptor 2, which has its C-2
amino group masked as azide. The presence of the latter func-
tional group is important because after oxidative removal of
the Nap ether, an acceptor is formed (6) that sterically is suffi-
ciently unencumbered for glycosylation with fucosyl donor 3.
The latter compound also has a removable PMB ether allowing
the installation of an 1,2-fucoside using donor 4. After assem-
bly of a tetrasaccharide, the azide can be converted into Troc
and a glycosylation with properly protected aminopentanol
will give linker modified compound LDN-DF (19) as only the b-
anomer.
A TMSOTf-mediated glycosylation of N-phenyl trifluo-raceti-
midate donor 1 with acceptor 2 afforded disaccharide 5 in a
yield of 91 %. The Nap ether of 5 was removed using DDQ in a
mixture of DCM and H2O to give acceptor 6 in a yield of 84 %.
Next, fucosyl donors 3 and 4, having Bn and PMB ether at C-2,
respectively, were preactivated with DPS/ Tf2O in the presence
of TTBP at @60 8C,[11] which was followed by the addition of ac-
ceptor 6. The resulting reaction mixture was allowed to slowly
warm to @40 8C resulting in formation of trisaccharides 7 and
13, which were isolated as mainly the a-anomers in good yield
(7, 68 %; J1,2 = 3.5 Hz;
1JC,H = 174.9 Hz) and (13, 73 %; J1,2 =
3.8 Hz; 1JC,H = 175.4 Hz). Alternative glycosylation conditions re-
sulted in poor anomeric selectivity (Table S1). Trisaccharide 7
was further modified with an anomeric aminopentyl linker and
to attain b-anomeric selectivity, the azide was converted into
NHTroc (!8) by a two-step procedure entailing reduction
using triphenyl phosphine followed by reaction of the result-
Table 1. Major glycan structures of Schistosoma mansoni egg proteins.




ing amine with TrocCl. Next, glycosyl donor 10 was prepared
by removal of the anomeric TDS ether of 8 with HF/pyridine
followed by reaction with N-phenyl trifluoroacetimidate in the
presence of DBU. As anticipated, a TMSOTf mediated glycosyla-
tion of 10 with N-benzyloxycarbonyl-N-benzyl-5 aminopenta-
nol gave 11 as only the b-anomer in 87 % yield. The latter tri-
saccharide was globally deprotected by a three-step procedure
in which the NHTroc was converted to NHAc using zinc dust,
followed by global deacetylation and hydrogenation to pro-
vide spacer modified LDN-F 12. A number of alternative strat-
egies were explored to prepare LND-F, and it was found that
judicious selection of amino protecting groups was critical,
and the use of bulky protecting groups such as N-phthalimido
resulted in a donor-acceptor reactivity mismatch, resulting in
almost immediate hydrolysis or degradation of donor
(Table S1). In addition to donor 4 having a temporary PMB
ether, several alternatives were examined but these gave dis-
appointing results (Table S1). Next, attention was focused on
the preparation of spacer modified LDN-DF 20. Thus, treat-
ment of trisaccharide 13 with DDQ in DCM/H2O afforded ac-
ceptor 14. Several reaction conditions were explored (Table S2)
to install a fucoside, and tetrasaccharide 15 was obtained with
high a-anomeric selectivity in good yield (83 %) when the gly-
cosylation was performed in DCM in the presence of DMF[12]
and promoted by 1 equivalent of TMSTOf at @20 8C followed
by slow warming to + 5 8C (J1,2 = 3.9 Hz;
1JC,H = 173.3 Hz). The
anomeric TDS group of 15 was removed and the resulting
lactol (17) converted into a N-phenyl trifluoroacetimidate 18,
which was coupled with N-benzyloxycarbonyl-N-benzyl-5-ami-
nopentanol to give 19. Global deprotection of the latter com-
pounds gave target tetrasaccharide 20 in an overall good yield
(37 % over three steps).
Molecular basis of binding of LDN-F and LDN-DF to DC-SIGN
The molecular basis of the interactions of DC-SIGN with LDN-F
(12) and LDN-DF (20) in solution was examined by combining
saturation transference difference (STD-NMR), chemical shift
perturbation analysis of the protein backbone, nuclear Over-
hauser effect (NOE) evaluation, and molecular modeling. The
NMR-based strategy combines molecular recognition analysis
from the perspective of the protein and ligand thereby provid-
ing a detailed atomic view of the interactions. 1H-STD-NMR ex-
periments were performed to establish which parts of LDN-F
and LDN-DF make direct contacts with the lectin. 1H–15N HSQC
experiments on the 15N-labeled carbohydrate recognition
domain (CRD) of DC-SIGN were conducted to identify protein
residues involved in ligand binding and to establish whether
differences exist between the two epitopes. Furthermore, 1H–
15N HSQC titration experiments provided binding affinity esti-
mations. Finally, trNOESY experiments characterized the ligand
conformation in the bound state and additionally provided
short intermolecular distances between the ligand and the
protein, thus defining the precise binding pose.
1H Saturation transfer difference (STD) NMR
1H-STD NMR spectra resulting from the interaction of LDN-F
and LDN-DF with DC-SIGN extracellular domain (ECD) which
tetramerizes in solution, along with the corresponding refer-
ence spectra are shown in Figures 1 a and b, respectively. It
demonstrates that DC-SIGN can bind both glycans but with
substantial differences in binding mode. Both ligands bind
through the terminal fucoside. The STD data for LDN-F are sim-
ilar to those previously reported for the structurally related Lex
tri-saccharide,[6b] indicating a similar mode of binding. As for
Lex, LDN-F is recognized by DC-SIGN through the fucoside and
additional contacts are made with the GalNAc pyranosyl ring
and the N-acetyl group of the GlcNAc moiety. The N-acetyl
moiety of GalNAc exhibited only a weak STD effect, indicating
that it does not contribute substantially to binding (Figure 1 a).
Detectable STD effects of the interaction of DC-SIGN with LDN-
Scheme 1. Synthesis of LDN-F and LDN-DF epitopes. Reagents and condi-
tions: i) TMSTOf, DCM, @30 8C, 91 %; ii) DDQ, DCM, DCM/H2O, 84 %; iii) DPS/
Tf2O, DCM, @60 8C to @40 8C, 68 % for 7 and 73 % for 13 ; iv) (a) PPh3, THF/
H2O (b) trocCl, NEt3, DCM, 63 % (over two steps); v) HF/py in pyridine;
vi) 2,2,2-Trifluoro-N-phenylacetimidoyl chloride, DBU, DCM; vii) HO(CH2)5
N(Bn)Cbz, TMSTOf, DCM, @30 8C, 66 % (over 3 steps) ; viii) (a) Zn dust, AcOH,
Ac2O, THF (b) NaOMe, MeOH (c) Pd/C, H2, H2O/MeOH, 45 % (over three
steps) ; ix) DDQ, DCM/H2O, 74 %; x) TMSTOf, DCM/DMF, @30 8C to + 5 8C,
83 %; xi) (a) PPh3, THF/H2O (b) TrocCl, NEt3, DCM; xii) HF/py in pyridine;
xiii) 2,2,2-Trifluoro-N-phenylacetimidoyl chloride, DBU, DCM; xiv) HO(CH2)5
N(Bn)Cbz, TMSTOf, DCM, @30 8C, 31 % (over five steps) ; xv) (a) Zn dust, AcOH,
Ac2O, THF (b) NaOMe, MeOH (c) Pd/C, H2, H2O/MeOH, 37 % (over three
steps).




DF were restricted to H2, H4 and Me of the terminal 1,2-fuco-
side with a remarkable absence of STD signals from the inter-
nal 1,3-fucoside and the GalNAc and GlcNAc moieties (Fig-
ure 1 b). The much lower intensities of the STD signals of the
LDN-DF compared to those acquired for the LDN-F suggests
weaker binding of the former. The blank 1H-STD NMR experi-
ments of LDN-F and LDN-DF ligands alone are shown in the
Supporting Information (Figures S1 and S2).
Chemical shift perturbation analysis
The primary carbohydrate binding site of DC-SIGN is com-
posed of an extended loop (from W343 to D355) and residues
in b-strand-4 (from N363 to D367), which surround the princi-
pal Ca+ 2 ion.[9b] Additionally, residues in b-strands-3 and @2
(from E356 to G361 and F313, respectively) shape a secondary
binding region. Chemical shift perturbation analysis using the
Figure 1. 1H-STD-NMR spectra for the interaction of full-length DC-SIGN with (a) LDN-F and (b) LDN-DF. Relative STD and epitope mapping are shown on the
left side for both ligands and refer to double difference between the STD spectrum in the presence of the protein and that in the absence of it. STD spectra
were acquired in the same conditions, however, drastic difference in absolute STD intensities between the two ligands exist. Specifically, the maximum STD
signal detected for LDN-DF ligand corresponds to just the 25 % of the strongest STD signal detected for the LDN-F. (c) Average chemical shift perturbation
upon the addition of 100 equivalents of LDN-F (red) and LDN-DF (blue) respect to the protein. The cut-offs values were determined as “mean:SD” and are
indicated with dotted lines. Structural models for the complexes of CRD DC-SIGN with the LDN-F ligand (d) and the LDN-DF ligand (e) obtained from MD sim-
ulations.




15N-labeled protein was performed to examine which residues
of the CRD of DC-SIGN interact with the glycans. Thus, the 15N-
labeled CRD DC-SIGN was titrated with LDN-F and LDN-DF and
1H-15N-HSQC spectra were acquired at every titration point
(Figure S3). Both ligands provided similar chemical shift pertur-
bation (CSP) profiles involving amino acids of the primary and
secondary binding site. However, upon addition of the same
number of equivalents, the CSP of the lectin backbone NH res-
onances were much larger for LDN-F than for LDN-DF (Fig-
ure 1 c), indicating weaker binding of the latter compound. In-
deed, fitting of the CSP to the corresponding binding iso-
therms for LDN-F yielded a kD of 1.5:0.4 mm (Figure S3). Pro-
tein saturation was not possible with LDN-DF providing an im-
precise kD estimation, but substantially larger than 6 mm.
Transferred NOESY
Recently,[13] the molecular complexes of DC-SIGN with A and B
histo blood group antigens have been studied by trNOESY ex-
periments. Key intermolecular NOEs between the Hg protons
of V351 with H1 and H2 of the fucoside moiety were observed.
The importance of the van der Waals stabilizing contacts in-
volving the Me groups of V351 for the recognition of
branched fucosylated epitopes has also been shown by X-ray
crystallography,[6a] and is in agreement with mutagenesis stud-
ies, demonstrating that substitution of this residue has impor-
tant implications for the binding of Lewis type epitopes.[14]
Therefore, a trNOESY experiment was carried out for LDN-F in
the presence of 0.2 equivalents of the CRD of DC-SIGN. After
addition of the protein to the NMR tube, strong negative NOE
were observed for the ligand protons, which contain informa-
tion on the bound ligand conformation. Inter-molecular NOE
correlations between the methyl groups of V351 and H1-Fuc,
H2-Fuc, and the methyl group of GlcNAc were observed
(Figure 2). Consistent with the STD analysis, Fuc H1 and H2 are
in close contact with the lectin. Moreover, the strong STD de-
scribed above for the methyl moiety of the GlcNAc residue is
supported by the tr-NOE correlation between this group and
V351. As control, the NOESY spectrum of the free ligand was
measured which displayed very weak negative NOE effects.
Unfortunately, a good tr-NOESY spectrum could not be record-
ed for the LDN-DF complex, probably due to its rather low
binding affinity.
Molecular modeling
The NMR data were employed to derive three-dimensional
models for the complexes of DC-SIGN with LDN-F and LDN-DF.
For LDN-F, the experimental STD and intermolecular NOE data
showed close contacts of H1-Fuc, H2-Fuc and Ac-GlcNAc with
the methyl group of V351 of the protein. For the histo blood A
and B antigens,[15] it has been demonstrated that DC-SIGN
binds the fucosyl ring exclusively through coordination of the
C-3 and C-4 hydroxyls with the Ca2 + ion. The crystallographic
structure of DC-SIGN complexed with Lex (pdb code 1SL5) also
fulfills this requirement.[6a] Therefore, the pyranosyl ring of
LDN-F was superimposed onto the corresponding monosac-
charide in the deposited 1SL5 structure. The resulting binding
pose was minimization by MD simulation that resulted in a
structure that is in excellent agreement with the experimental
data, including HSQC chemical shift perturbation and epitope
mapping through STD. For LDN-DF, a similar approach was
used by superimposing the terminal 1,2-linked fucoside in the
primary Ca2 + binding site. This starting binding pose placed
H2 of the terminal fucoside in close proximity to the protein
backbone, which is in agreement with the STD data. The alter-
native binding pose through the inner fucoside was discarded
due to steric clashes. Analysis of the MD trajectory showed
that for the complex of LDN-F with DC-SIGN, the ligand confor-
mation remained fairly well defined as revealed by the low dis-
persion of the f and y angles (Figure S4). This arrangement
favors hydrophobic contacts between V351 and the Fuc and
GlcNAc moieties, which were maintained throughout the
entire MD run (Figure 1 d). Additionally, the bound geometries
were validated by simulating the STD spectrum with CORCE-
MA-ST.[16] The match between the expected and the experi-
mental STD intensities for LDN-F was excellent, further sup-
porting the proposed binding model (Figure S5).
The derived bound structure for LDN-DF was very different
(Figure 1 e). In this case, the LDN backbone was far from the
protein with only the terminal fucoside making interactions. In
this case, the contacts between the Ac of GlcNAc and Hg pro-
tons of V351 were only transient and there was not a preferen-
tial spatial arrangement of both groups to make substantial
van der Waals contacts. Although the LDN-F moiety of LDN-DF
preserved conformational rigidity, the a1,2-fucoside linkage
was rather flexible (Figure S1) providing a loosely defined epi-
tope presentation around the primary binding site. In this
case, the fitting between the CORCEMA-ST simulations with
the experimental STD was less accurate, which is probably due
to the weak STD signals and the inability of the MD simulation
to reproduce the flexibility of the complex.
Figure 2. (a) NOESY spectrum of the complex of DC-SIGN with LDN-F. (b, c
and d) The quest of protein/ligand intermolecular NOEs. (e) Three-dimen-
sional model from the MD simulation showing the key intermolecular NOEs
between the ligand and the V351 residue of the lectin.




Glycan microarray binding studies
The CRDs of DC-SIGN are clustered in tetramers, and such an
arrangement can greatly amplify the avidity and specificity
when interacting with glycans epitopes that are present in a
multivalent arrangement.[8b–17] To examine the importance of
multivalency, LDN-F (12) and LDN-DF (20) and a number of
control glycans including Lex (21), Lex-Lex (22), SLex (23) and
SLex-Lex (24), which all are equipped with an anomeric amino-
pentyl moiety, were immobilized on N-hydroxysuccinimide
(NHS)-activated glass slides in replicates of 6 by piezoelectric
printing. After incubation overnight in a saturated NaCl cham-
ber, unreacted esters were quenched with ethanolamine. First,
the glycan microarray was probed with biotinylated Aleuria
aurantia lectin, which recognizes a1,2- a1,3- and a1,6-fuco-
sides, and Streptavidin-AlexaFluor635. As anticipated all com-
pounds showed strong responsiveness (Figure S3) confirming
proper spot morphology and printing. Next, sub-arrays were
incubated with various concentrations of recombinant human
DC-SIGN-Fc chimera premixed with anti-IgG Fc-biotin and
Streptavidin-AlexaFluor635 in TSM binding buffer containing
Ca2 + . After incubation for 1 h, the slide was washed, dried by
centrifugation and scanned for fluorescence intensity. LDN-F
(12), Lex (21) and Lex-Lex (22) exhibited strong responsiveness
whereas no binding was detected for LDN-DF (20) (Figure 3).
This observation indicates that the avidity and selectivity of
binding is greatly enhanced when the binding is probed on a
multivalent surface. At a higher concentration of DC-SIGN,
SLex-Lex (24) also exhibited responsiveness whereas this was
not the case for SLex, indicating that the internal Lex moiety
can be recognized by DC-SIGN. When the microarray binding
studies were performed in the absence of Ca2 + , no binding
was observed confirming specificity of binding.
Conclusions
The recognition of fucosylated structures such as Lex, LDN-F
and pseudo_Ley, by DC-SIGN has been implicated in schistoso-
miasism,[5a–18] resulting in modulation of innate and adaptive
immune responses.[19] Further fucosylation of these epitopes to
give structures such LDN-DF or DF-LDN-DF abolishes bind-
ing.[3a] During the life cycle of S. mansoni, fucosylated glycans
such as LDN, Lex, LDN-F and LDN-DF are expressed in a stage-
dependent manner, thereby shaping host immune respon-
ses.[3c–20] We have investigated, at a molecular level, in which
way the terminal 1,2-fucoside of LDN-DF influences recognition
by DC-SIGN. Such a study required well-defined glycans, which
were obtained by a chemical approach in which amino pro-
tecting groups were carefully selected to facilitate high yield-
ing and stereoselective chemical glycosylations. The molecular
recognition of LDN-F and LDN-DF by DC-SIGN was studied by
NMR assisted by molecular modeling, which revealed that in
solution it can recognize both glycans but with substantial dif-
ferences in affinity and binding mode. The HSQC titration ex-
periments provided a dissociation constant for LDN-F of 1.5:
0.4 mm at the monovalent level, whereas the kD for LDN-DF
could only be estimated but is substantially larger than 6 mm.
In the case of the LDN-F, the a1,3-fucoside coordinates with
the Ca2+-ion of the CRD of DC-SIGN, placing the GlcNAc resi-
due in close proximity to the protein surface thereby allowing
for additional interactions. The affinity and structural model for
LDN-F and Lex are very similar,[6b] indicating that the presence
of a b4GalNAc vs. a b4Gal moiety does not substantially alter
binding. The terminal a1,2-linked fucoside of LDN-DF can also
bind into the canonical binding site of DC-SIGN but in this
case, the GlcNAc and GalNAc residues are placed away from
the protein surface preventing additional contacts, and as a
result the binding affinity is approximately an order of magni-
tude lower.
Previous studies have shown that antibodies directed
against Lex and LDN-F can block the binding of DC-SIGN to
soluble egg antigen of S. mansoni whereas an antibody against
LDN-DF had no effect on binding.[3a, 21] These observations lead
to the conclusion that DC-SIGN can recognize Lex and LDN-F
but not LDN-DF. Our studies have shown that LDN-DF can in-
teract with DC-SIGN albeit with a substantial lower affinity
than for Lex and LDN-F. The glycan microarray studies demon-
strated that the avidity and selectivity of binding is greatly en-
hanced when the glycans are presented in a multivalent
manner, and in this format Lex and LDN-F gave strong respon-
siveness whereas no binding was detected for LDN-DF. The ex-
tracellular domain of DC-SIGN occurs as a tetramer. Further-
more, the glycans of S. mansoni are presented on its cell sur-
face as glycoproteins and glycolipids, and thus it is anticipated
that such assemblies can make multivalent interactions with
DC-SIGN, resulting in enhancement in avidity[8b] and magnify
selectivities.[22]
Recently, it was shown that schistosomula extracellular vesi-
cles (EVs) carry surface glycoproteins and glycolipids with a
specific subset of fucosylated structures, such as Lex, pseudo_
Ley and LDN-F motifs that mediate internalization by moDCs in
Figure 3. Microarray results of the glycan library printed at 100 mm for bind-
ing to DC-SIGN (3 and 10 mg mL@1). Bars represent the mean:SD.




a DC-SIGN dependent manner.[23] It is also known that DC-SIGN
signaling via fucosides decreases pro-inflammatory respons-
es,[24] indicating that S. mansoni may exploit these structures to
dampen host immune response. Fucosylated glycans such as
LDN, Lex, LDN-F and LDN-DF are expressed in a stage-depen-
dent manner during the life cycle of S. mansoni.[25] Interesting-
ly, an increase in di-fucosylated N-glycans and glycolipids
occurs during the transition from immature to mature eggs
and in the miracidia stage.[20, 26] During these stages, ligands,
for DC-SIGN such as Lex, are expressed at low levels. Thus, it is
like that these changes result in a lack of detection by DC-
SIGN, thereby modulating the host’s immune system.
Further studies are required to determine the importance of
the density of specific glycans during the different life stages
of Schistosomes and their influence on DC-SIGN detection and
subsequent skewing of host immune responses. Structures
such as LDN-DF and LDN-F are part of complex oligosacchar-
ides in which multiple of these epitopes can be presented. Po-
tentially, such structures can make multivalent interactions
leading to high avidity of binding. These features of molecular
recognition require further investigation. In addition to DC-
SIGN, other C-type lectins have been implicated in sensing hel-
minth glycans by human DCs. Among those, the macrophage
galactose-type lectin MGL exhibits high specificity for S. man-
soni glycans terminating in Gal-NAc.[27] It is conceivable that
these lectins act in concert to detect patterns of glycans there-
by shaping immune responses. Finally, the synthetic ap-
proaches of LDN-F and LDN-DF will promote further biological
studies to address the role of uniquely fucosylated glycans in
S. mansoni infectivity and may lead to the development of
immune-modulatory compounds.
Experimental Section
General procedure for glycosylations for the synthesis of 7 and
13 : Thioglycoside donor (4 equiv), diphenyl sulfoxide (4 equiv) and
2,4,6-tri-tert-butylpyrimidine (4 equiv) were dissolved in DCM and
stirred in the presence of pre-activated molecular sieves (4 a) for
30 min. Next, the temperature was lowered (@60 8C), followed by
the addition of trifluromethanesulfonic anhydride (4 equiv). A solu-
tion of acceptor (1 equiv) in anhydrous DCM was added dropwise
along the wall of the flask and the reaction was left stirring while
the temperature was slowly raised to @40 8C. The reaction was
quenched with triethyl amine, the molecular sieves were filtered
off, and DCM was removed in vacuo. The residue was purified by
silica gel column chromatography.
General procedure for conversion of azide (N3) into NHTroc :
Compounds 7 and 13 (1 equiv) were dissolved in THF and water
was added. Next trimethylphosphine (5 equiv) was added. The re-
action mixture was stirred under an atmosphere of Ar for 2 h, after
which the solvent was evaporated in vacuo and the residue was
co-evaporated with toluene twice. The residue was dissolved in
DCM, followed by the addition of 2,2,2-trichloroethyl chloroformate
(2 equiv) and triethylamine (2 equiv). The reaction mixture was
stirred for 1 h after which it was diluted by DCM and washed with
water. The organic layer was dried (MgSO4), filtered, and the filtrate
concentrated in vacuo. The residue was purified by silica gel
column chromatography.
General procedure for the glycosylation of 5-(N-benzyloxycarbo-
nyl,N-benzyl)aminopentyl linker : The donors 10 and 18 (1 equiv)
and 5-(N-benzyloxycarbonyl,N-benzyl)aminopentyl linker (5 equiv)
were dissolved in DCM, and stirred in the presence of pre-activated
molecular sieves (4 a) under an atmosphere of Ar for 30 min. The
reaction mixture was cooled (@50 8C), followed by the addition of
trifluoromethanesulfonic acid (0.2 equiv). The temperature was
slowly warmed up to @30 8C, after which TLC showed complete
consumption of donor and the formation of a new product. The
reaction mixture was quenched with triethyl amine, the molecular
sieves were filtered off, and the solvent was evaporated. The resi-
due was purified by silica gel column chromatography.
Protein expression : The extracellular domain of DC-SIGN was ob-
tained as previously de-scribed.[15] The carbohydrate recognition
domain of DC-SIGN in its 15N labelled form was obtained as previ-
ously described.[13]
1H Saturation transfer difference (STD) NMR : The samples for sat-
uration-transfer difference (STD) NMR experiments were prepared
using the extracellular domain of DC-SIGN at 10 mm concentration
in 25 mm Tris-d11, 150 mm NaCl, 4 mm CaCl2 in D2O (pD 8) using
lectin/ligand ratios of 1:60. The temperature was set to 298 K. STD
experiments were performed at 600 MHz Bruker spectrometer,
using standard Bruker pulse sequences without water suppression
nor protein spin-lock filter. Protein saturation was achieved with a
Gaussian-shaped pulse of 49 ms. The on-resonance frequency was
set at aliphatic regions (0.76 ppm) and the off-resonance frequency
at 100 ppm. Blank STD experiments of the ligands alone were ac-
quired in the same conditions. The results of blank 1H-STD NMR ex-
periments for ligands 12 and 20 are shown in Figures S1 and S2,
respectively.
Chemical shift perturbation analysis : 1H-15N-HSQC-based experi-
ments were performed using 15N-labeled CRD DC-SIGN at 50 mm,
with 2 mm DTT-d10, at 800 MHz Bruker spectrometer equipped
with a cryoprobe, at 310 K. Eight and ten titration points were ac-
quired for ligands 12 and 20 respectively, with ligand concentra-
tions varying from 0 to 0.5 mm for the former and from 0 to
1.5 mm for latter. Averaged chemical shift perturbation (CSP) and
dissociation constants (kD) were calculated using the CcpNmr Anal-
ysis 2.4.2.3 The chemical shift perturbation analysis was performed
based on the protein backbone assignment deposited in the BMRB
database with the code 27854. The results from this analysis are
shown in Figure S3.Transferred NOESY spectrum for glycan 12, was
acquired at 800 MHz Bruker spectrometer equipped with a cryop-
robe in the presence of 0.2 equivalents of DC-SIGN (180 mm of pro-
tein), with a mixing time of 400 ms, at 298 K.
Molecular modelling : Initial geometries of ligands 12 and 20 were
built in the Glycam web (http://glycam.org). Proton–proton distan-
ces derived from NOESY spectra (using the isolated spin-pair ap-
proximation) were used to check the goodness of the minimized
structures. The initial pdb coordinates for CRD of DC-SIGN were de-
rived from the crystal structure Protein Database (PDB) 1SL5. The
magnesium ion was replaced by calcium, and the fucose pyranose
ring of glycans 12 and 20 was superimposed onto the correspond-
ing sugar in the deposited 1SL5 structure. The resulting binding
poses were used as starting points for molecular dynamics (MD)
simulations. The MD simulations were performed using the
Amber16 program4 with the ff99SB force field parameters for pro-
tein and GLYCAM 06 h for the saccharides. Thereafter, the starting
3D geometries were placed into a 12 a octahedral box of explicit
TIP3P waters, and counterions were added to maintain electroneu-
trality. Two consecutive minimization stages were performed in-
volving (1) only the water molecules and ions and (2) the whole
system with a higher number of cycles, using the steepest de-




scent algorithm. The system was subjected to two rapid molecular
dynamic simulations (heating and equilibration) before starting the
real dynamic simulation. The equilibrated structures were the start-
ing points for the final MD simulations at constant temperature
(300 K) and pressure (1 atm). 500 ns Molecular dynamics simula-
tions without constraints were recorded, using an NPT ensemble
with periodic boundary conditions, a cut-off of 10 a, and the parti-
cle mesh Ewald method. A total of 250 000 000 molecular dynam-
ics steps were run with a time step of 1 fs per step. Coordinates
and energy values were recorded every 10 000 steps (10 ps) for a
total of 25 000 MD models. A detailed analysis of the glycosydic
linkages for glycans 12 and 20 was performed along the MD tra-
jectory using the cpptraj module included in Amber-Tools 16 pack-
age and are represented in Figure S4.
Microarray : The synthetic compounds were printed at 100 mm on
activated glass slides by piezoelectric non-contact printing (sci-
FLEXARRAYER S3, Scienion Inc). Printing was validated by assaying
the binding to biotinylated Aleuria aurantia lectin (AAL) and detec-
tion by Streptavidin-AlexaFluor635 (see Figure S6). Recombinant
human DC-SIGN-Fc Chimera was assayed premixed with anti-IgG
Fc-biotin and Streptavidin-AlexaFluor635. The fluorescence was
measured using a GenePix 4000 B microarray scanner (Molecular
Devices) and data were processed with GenePix Pro 7 software
and further analyzed using our home written Microsoft Excel
macro. Data were fitted using Prism software (GraphPad Software,
Inc). Further details are given in the Supporting Information.
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